EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Tozorakimab to Prevent COPD Exacerbations

Frank C Sciurba, Henrik Watz, Arnaud Bourdin, Wim Janssens, Fernando J Martinez, Jinping Zheng, Maarten van den Berge, Matteo Bonini, MeiLan K Han, Dave Singh, Gerard J Criner, Christopher E Brightling und 18 weitere

New England Journal of Medicine · 29.10.2026 · 395 (17) · 1703-1716

DOI: 10.1056/nejmoa2606998 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 29.10.2026. Verfasst von Frank C Sciurba und 29 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Pittsburgh, Pittsburgh. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Interleukin-33, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: AstraZeneca United States.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalInterleukin-33Pulmonary Disease, Chronic ObstructiveAdultAgedFemaleHumansMaleMiddle AgedAdministration, InhalationAdrenergic beta-AgonistsDisease ProgressionDouble-Blind MethodDrug Therapy, CombinationEx-SmokersGlucocorticoidsInjections, SubcutaneousMuscarinic AntagonistsSmokersSmokingTreatment Outcome

Substanzen

Adrenergic beta-AgonistsAntibodies, MonoclonalGlucocorticoidsInterleukin-33Muscarinic Antagonists

Autor:innen und Institutionen

  • Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Pittsburgh, Pittsburgh.
  • Velocity Clinical Research Germany, Ahrensburg, Germany.
  • Department of Pulmonology, University of Lübeck, Lübeck, Germany.
  • Airway Research Center North, German Center for Lung Research, Lübeck, Germany.
  • PhyMedExp, University of Montpellier, Centre National de la Recherche Scientifique, INSERM, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
  • Respiratory Division, Department of Chronic Diseases and Metabolism, Katholieke Universiteit Leuven, Leuven, Belgium.

Förderung

  • AstraZeneca United States

Zitieren

APA

Sciurba, F. C., Watz, H., Bourdin, A., Janssens, W., Martinez, F. J., Zheng, J., van den Berge, M., Bonini, M., Han, M. K., Singh, D., Criner, G. J., Brightling, C. E., Papi, A., Bhatt, S. P., Jenkins, M., Mikosz, M., Chołbiński, P., Ziemiecka, M., Löfdahl, M., …, & TITANIA Trial Investigators (2026). Tozorakimab to Prevent COPD Exacerbations. New England Journal of Medicine, 395(17), 1703-1716. https://doi.org/10.1056/nejmoa2606998

Vancouver

Sciurba FC, Watz H, Bourdin A, Janssens W, Martinez FJ, Zheng J, et al. Tozorakimab to Prevent COPD Exacerbations. New England Journal of Medicine. 2026;395(17):1703-1716. doi:10.1056/nejmoa2606998

BibTeX
@article{Sciurba2026,
  author = {Sciurba, Frank C and Watz, Henrik and Bourdin, Arnaud and Janssens, Wim and Martinez, Fernando J and Zheng, Jinping and van den Berge, Maarten and Bonini, Matteo and Han, MeiLan K and Singh, Dave and Criner, Gerard J and Brightling, Christopher E and Papi, Alberto and Bhatt, Surya P and Jenkins, Martin and Mikosz, Marta and Chołbiński, Piotr and Ziemiecka, Monika and Löfdahl, Magnus and Arya, Deepa and Yadavalli, Madhavi and Brodek, Bryan H and Fagerås, Malin and Bardsley, Samuel and Martin, Neil and Patel, Rajesh and Psallidas, Ioannis and OBERON and TITANIA Trial Investigators, OBERON and TITANIA Trial Investigators and OBERON Trial Investigators, OBERON Trial Investigators and TITANIA Trial Investigators, TITANIA Trial Investigators},
  title = {Tozorakimab to Prevent COPD Exacerbations},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {17},
  pages = {1703--1716},
  doi = {10.1056/nejmoa2606998}
}
Kostenlos starten →